July 2016: Regenera Completes Phase 2a study in NAION and releases preliminary results


After 6 months of treatment, 36.4% (4 of 11 eyes) in the RPh201-treated group improved by ≥15 letters of visual acuity and 56% (6 of 11 eyes) improved by 10 lines, compared to only 12.5 % (1 of 8 eyes) in the placebo group

The proportion of subjects improving by ≥3 lines (≥15 letters) in best-corrected ETDRS visual acuity used as the primary endpoint Identical to the clinically meaningful endpoint accepted by FDA and planned for the Phase 3 trial. The efficacy analysis performed on the 19 subjects who completed all visits.